← Back to Search

Treatment for Crohn's Disease (EVOLVE Trial)

N/A
Waitlist Available
Research Sponsored by Takeda
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline up to 36 months post-index date
Awards & highlights

Summary

The main aim of this study is to compare long-term remission in participants receiving vedolizumab (VDZ) and those receiving ustekinumab (UST). In this study, the study doctors will review each participant's past medical records. This study is about collecting existing information only; participants will not receive treatment or need to visit a study doctor during this study.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline up to 36 months post-index date
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline up to 36 months post-index date for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Cumulative Rates of Clinical Remission Over 36 Months Compared Between VDZ and UST Cohorts
Secondary study objectives
Cumulative Rates of CS-free Response Over 36 Months Compared Between VDZ and UST Cohorts
Cumulative Rates of CS-free Response of Subsequent Line Treatments Compared Between VDZ and UST Cohorts
Cumulative Rates of Clinical Remission Over 30 Months Compared Between VDZ and UST Cohorts
+25 more

Find a Location

Who is running the clinical trial?

TakedaLead Sponsor
1,227 Previous Clinical Trials
4,221,882 Total Patients Enrolled
Study DirectorStudy DirectorTakeda
1,252 Previous Clinical Trials
503,756 Total Patients Enrolled
~166 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top